**Daré Bioscience Awarded Up to $499,000 Grant from Gates Foundation to Support Global Preeclampsia Research** SAN DIEGO, Sept. 24, 2025 - Daré Bioscience Inc. (NASDAQ: DARE) announced today it has been awarded up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for global research projects targeting preeclampsia, a serious and underserved pregnancy complication. The funding is part of the Gates Foundation's Grand Challenges initiative and will benefit multiple organizations conducting pre-clinical research focused on the prevention, diagnosis, and treatment of preeclampsia worldwide. Daré's role will include strategic mentorship and technical guidance to grantee organizations, aiming to advance innovative solutions for a condition that remains a leading cause of maternal and infant mortality, and for which no FDA-approved treatments currently exist.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534154-en) on September 24, 2025, and is solely responsible for the information contained therein.
Comments